Evaluation of Nuclear Factor of Activated T-cells (NFATc1) Expression in Non-metastatic Osteosarcoma Tissue

Evaluation of NFATc1 in Osteosarcoma
Vol. 21 No. 2 : 2026 (699-712)

Syurahbil Abdul Halim
Syurahbil Abdul Halim
Department of Orthopaedics, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia Hospital Pakar Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan Malaysia
Jufithri Abd Halim
Jufithri Abd Halim
Department of Orthopaedics, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia Hospital Pakar Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan Malaysia Sena Healthcare Service Sdn Bhd, Seri Petaling, 57000 Kuala Lumpur, Malaysia
Sahran Yahya
Sahran Yahya
Department of Orthopaedics, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia Hospital Pakar Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan Malaysia
Wan Faisham Numan Wan Ismail
Wan Faisham Numan Wan Ismail
Department of Orthopaedics, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia Hospital Pakar Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan Malaysia Prince Court Medical Center, 50450 Kuala Lumpur, Malaysia
Sharifah Emilia Tuan Sharif
Sharifah Emilia Tuan Sharif
Hospital Pakar Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan Malaysia Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
Muhamad Syahrul Fitri Zawawi
Muhamad Syahrul Fitri Zawawi
Department of Orthopaedics, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia Hospital Pakar Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan Malaysia

Abstract
Osteosarcoma, a primary malignant bone tumour, poses significant challenges in treatment and prognosis despite advancements in therapy. The expression of nuclear factor of activated T cells c1 (NFATc1) in osteosarcoma tissue remains underexplored as a potential therapeutic target. This study aimed to evaluate NFATc1 protein expression in human non-metastatic osteosarcoma tissue samples and its correlation with patient survival and its subtypes. Secondarily, we examined the association between clinico-demographic details and survival of osteosarcoma patients. A cross-sectional study was conducted on 31 patients with primary non-metastatic osteosarcoma. Immunohistochemical analysis was used to assess NFATc1 protein expression in surgically resected tissue specimens. Demographic data, treatment details and follow-up records were collected for analysis. The study population had a mean age of 20.0 years, with Malay ethnicity being predominant. NFATc1 protein expression was positive in 25.8% of cases predominantly in conventional osteosarcoma (30.4%). No significant correlation was found between NFATc1 protein expression and patient survival (p = 0.685) or osteosarcoma subtypes (p = 0.642). NFATc1-positive patients had lower odds of long-term survival compared to NFATc1-negative patients (OR = 0.550; 95% CI: 0.106 - 2.860), although this association was not statistically significant (p = 0.477). Among the clinico-demographic characteristics, only the type of surgery (limb salvage vs. amputation) showed a statistically significant association with survival (p = 0.002), while age, race, gender, site, pathological fracture, chemotherapy and surgery for recurrence did not. Therefore, NFATc1 alone does not appear to be a useful prognostic biomarker in non-metastatic osteosarcoma. Further study is recommended to explore NFATc1 in larger cohort of both non-metastatic and metastatic osteosarcoma.

Keywords : Immunohistochemistry; NFATc1; osteosarcoma; prognosis; survival,

Correspondance Address
*Correspondence: msf.zawawi@usm.my

References

Akiyama, T., Dass, C., Choong, P.F. 2008. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 7(11): 3461-9. https://doi.org/10.1158/15357163.MCT-08-0530 

Avnet, S., Longhi, A., Salerno, M., Halleen, J., Perut, F., Granchi, D., Ferrari, S., Bertoni, F., Giunti, A., Baldini, N. 2008. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol 33(6): 1231-8. 

Bacci, G., Briccoli, A., Longhi, A., Ferrari, S., Mercuri, M., Faggioli, F., Versari, M., Picci, P. 2005. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 44(7): 748-55. https://doi.org/10.1080/02841860500327503 

Bielack, S., Kempf-Bielack, B., Branscheid, D., Carrle, D., Friedel, G., Helmke, K., Kevric, M., Jundt, G., Kühne, T., Maas, R., Schwarz, R., Zoubek, A., Jürgens, H. 2009. Second and subsequent recurrences of osteosarcoma: Presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 27(4): 557-65. https://doi.org/10.1200/JCO.2008.16.2305 

Bratthauer, G.L. 2010. The avidin-biotin complex (ABC) method and other avidin-biotin binding methods. Methods Mol Biol 588: 257-70. https://doi.org/10.1007/978-1-59745-324-0_26

Browne, R.H. 1995. On the use of a pilot sample for sample size determination. Stat Med 14(17): 1933-40. https://doi.org/10.1002/sim.4780141709 

Buchholz, M., Schatz, A., Wagner, M., Michl, P., Linhart, T., Adler, G., Gress, T., Ellenrieder, V. 2006. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J 25(15): 3714-24. https://doi.org/10.1038/sj.emboj.7601246

Chua, H.H., Tuan Sharif, S.E., Wan Ismail, W.F.N., Zawawi, M.S.F., Abdullah, S. 2021. Evaluation of the receptor activator of nuclear factor kappa B ligand (RANKL) expression in osteosarcoma and its association with the clinicopathological data. Asian Pac J Cancer Prev 22(3): 741-7. https://doi.org/10.31557/APJCP.2021.22.3.741

Endo-Munoz, L., Evdokiou, A., Saunders, N.A. 2012. The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochim Biophys Acta 1826(2): 434-42. https://doi.org/10.1016/j.bbcan.2012.07.003 

Faisham, W.I., Mat Saad, A.Z., Alsaigh, L.N., Nor Azman, M.Z., Kamarul Imran, M., Biswal, B.M., Bhavaraju, V.M., Salzihan, M., Hasnan, J., Ezane, A., Ariffin, N., Norsarwany, M., Ziyadi, M., Wan Azman, W., Halim, A., Zulmi, W. 2017. Prognostic factors and survival rate of osteosarcoma: A single-institution study. Asia Pac J Clin Oncol 13(2): e104-10. https://doi.org/10.1111/ajco.12346

Fletcher, C.D.M., Unni, K., Mertens, F. 2002. Pathology and genetics of tumours of soft tissue and bone. WHO Classification of Tumours: IARC Press. Giuliani, A., Colognesi, D., Ricco, T., Roncato, C., Capece, M., Amoroso, F., Wang, Q., De Marchi, E., Gartland, A., Di Virgilio, F., Adinolfi, E. 2014. Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma. PLoS One 9(9): e107224. https://doi.org/10.1371/journal.pone.0107224

Hanaki, S., Habara, M., Tomiyasu, H., Sato, Y., Miki, Y., Masaki, T., Shibutani, S., Shimada, M. 2024. NFAT activation by FKBP52 promotes cancer cell proliferation by suppressing p53. Life Sci Alliance 7(8): e202302426. https://doi.org/10.26508/lsa.202302426

Huang, B., Jiang, Z., Wu, S., Wu, H., Zhang, X., Chen, J., Zhao, F., Liu, J. 2021. RCAN1.4 suppresses the osteosarcoma growth and metastasis via interfering with the calcineurin/NFAT signaling pathway. J Bone Oncol 30: 100383. https://doi.org/10.1016/j.jbo.2021.100383 

Ishida, N., Hayashi, K., Hoshijima, M., Ogawa, T., Koga, S., Miyatake, Y., Kumegawa, M., Kimura, T., Takeya, T. 2002. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277(43): 41147-56. https://doi.org/10.1074/jbc.M205063200

Li, J., Sarosi, I., Yan, X, Morony, S., Capparelli, C., Tan, H., McCabe, S., Elliott, R., Scully, S., Van, G., Kaufman, S., Juan, S., Sun, Y., Tarpley, J., Martin, L., Christensen, K., McCabe, J., Kostenuik, P., Hsu, H., Fletcher, F., Dunstan, C.R., Lacey, D.L., Boyle, W.J. 2000. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 97(4); 1566-71. https://doi.org/10.1073/pnas.97.4.1566 

Li, Z., Zhang, Y., Li, Y., Xing, S., Li, S., Lyu, J., Ban, Z. 2022. PROSER2 is a poor prognostic biomarker for patients with osteosarcoma and promotes proliferation, migration and invasion of osteosarcoma cells. Exp Ther Med 24(6): 750. https://doi.org/10.3892/etm.2022.11686

Lin, Y., Song, Y., Zhang, Y., Shi, M., Hou, A., Han, S. 2023. NFAT signaling dysregulation in cancer: Emerging roles in cancer stem cells. Biomed Pharmacother 165: 115167. https://doi.org/10.1016/j.biopha.2023.115167

Liu, W., Hao, Y., Tian, X., Jiang, J., Qiu, Q. 2022. The role of NR4A1 in the pathophysiology of osteosarcoma: A comprehensive bioinformatics analysis of the single-cell RNA sequencing dataset. Front Oncol 12: 879288. https://doi.org/10.3389/fonc.2022.879288

Mirabello, L., Troisi, R., Savage, S. 2009a. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer 115(7): 1531-43. https://doi.org/10.1002/cncr.24121

Mirabello, L., Troisi, R., Savage, S. 2009b. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 125(1): 229-34. https://doi.org/10.1002/ijc.24320

Neal, J.W., Clipstone, N.A. 2003. A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. J Biol Chem 278(19): 17246-54. https://doi.org/10.1074/jbc.M300528200

Oikawa, T., Nakamura, A., Onishi, N., Yamada, T., Matsuo, K., Saya, H. 2013. Acquired expression of NFATc1 downregulates E-cadherin and promotes cancer cell invasion. Cancer Res 73(16): 5100-9. https://doi.org/10.1158/00085472.CAN-13-0274

Pan, M.G., Xiong, Y., Chen, F. 2013. NFAT gene family in inflammation and cancer. Curr Mol Med 13(4): 543-54. https://doi.org/10.2174/1566524011313040007

Papakonstantinou, E., Athanasiadou, K., Markozannes, G., Tzotzola, V., Bouka, E., Baka, M., Moschovi, M., Polychronopoulou, S., Hatzipantelis, E., Galani, V., et al. 2024. Prognostic factors in highgrade pediatric osteosarcoma among children and young adults: Greek Nationwide Registry for Childhood Hematological Malignancies and Solid Tumors (NARECHEM-ST) data along with a systematic review and meta-analysis. Cancer Epidemiol 90: 102551. https://doi.org/10.1016/j.canep.2024.102551

Perret, R., Escuriol, J., Velasco, V., Mayeur, L., Soubeyran, I., Delfour, C., Aubert, S., Polivka, M., Karanian, M., Meurgey, A., Le Guellec, S., Weingertner, N., Hoeller, S., Coindre, J., Larousserie, F., Pierron, G., Tirode, F., Le Loarer, F. 2020. NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker. Mod Pathol 33(10): 1930-44. https://doi.org/10.1038/s41379-0200542-z

Pilavaki, P., Gahanbani Ardakani, A., Gikas, P., Constantinidou, A. 2023. Osteosarcoma: Current concepts and evolutions in management principles. J Clin Med 12(8): 2785. https://doi.org/10.3390/jcm12082785

Shen, T., Yue, C., Wang, X., Wang, Z., Wu, Y., Zhao, C., Chang, P., Sun, X., Wang, W. 2021. NFATc1 promotes epithelial-mesenchymal transition and facilitates colorectal cancer metastasis by targeting SNAI1. Exp Cell Res 408(1): 112854. https://doi.org/10.1016/j.yexcr.2021.112854

Smeland, S., Bielack, S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M.D., Gorlick, R., Janeway, K., Ingleby, F., Anninga, J., et al. 2019. Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 109: 36-50. https://doi.org/10.1016/j.ejca.2018.11.027

Szuhai, K., Ijszenga, M., de Jong, D., Karseladze, A., Tanke, H., Hogendoorn, P. 2009. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res 15(7): 2259-68. https://doi.org/10.1158/1078-0432.CCR-08-2184  

Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J., Wagner, E.F., Mak, T.W., Kodama, T., Taniguchi, T. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3(6): 889-901. https://doi.org/10.1016/s15345807(02)00369-6 

Velupillai, P., Sung, C., Tian, Y., Dahl, J., Carroll, J., Bronson, R., Benjamin, T. 2010. Polyoma virusinduced osteosarcomas in inbred strains of mice: Host determinants of metastasis. PLoS Pathog 6(1): e1000733. https://doi.org/10.1371/journal.ppat.1000733

Wadhwa, N. 2014. Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors. Indian J Orthopaedics 48(3): 247-54. https://doi.org/10.4103/0019-5413.132497 

Wang, L., Mao, X., Yu, X., Su, J., Li, Z., Chen, Z., Ren, Y., Huang, H., Wang, W., Zhao, C., Hu, Y. 2024. FPR3 reprograms glycolytic metabolism and stemness in gastric cancer via calcium-NFATc1 pathway. Cancer Lett 593: 216841. https://doi.org/10.1016/j.canlet.2024.216841

Yasin, N., Abdul Rashid, M., Ajit Singh, V. 2020. Survival analysis of osteosarcoma patients: A 15-year experience. J Orthop Surg 28(1): 2309499019896662. https://doi.org/10.1177/2309499019896662

Zawawi, M.S.F., Dharmapatni, A.A.S.S.K., Cantley, M.D., McHugh, K.P., Haynes, D.R., Crotti, T.N. 2012. Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurinNFAT signalling during late stage osteoclast differentiation. Biochem Biophys Res Commun 427(2): 404-9. https://doi.org/10.1016/j.bbrc.2012.09.077

 

 


Positive NFATc1 from a 16-year-old boy with osteoblastic osteosarcoma distal femur. After the surgical resection, he underwent 6 courses chemotherapy with 95% necrosis. NFATc1 was found to be positive as shown, and he survived 10 years disease free (NFATc1: Nuclear factor of activated T cells c1)